Onconephrology Cancer, Chemotherapy and the Kidney
This case based resource focuses on kidney disease in patients with cancer. Chapters cover the pathophysiology and management of specific kidney diseases in cancer patients, as well as the impact of chemotherapy, toxicity of organ and stem cell tran
- PDF / 5,030,353 Bytes
- 385 Pages / 439.44 x 666.24 pts Page_size
- 19 Downloads / 176 Views
Kenar D. Jhaveri • Abdulla K. Salahudeen Editors
Onconephrology Cancer, Chemotherapy and the Kidney
Editors Kenar D. Jhaveri, MD Department of Medicine, Division of Kidney Diseases and Hypertension North Shore University Hospital and Long Island Jewish Medical Center Hofstra North Shore LIJ School of Medicine Great Neck New York USA
ISBN 978-1-4939-2658-9 DOI 10.1007/978-1-4939-2659-6
Abdulla K. Salahudeen, MD, MBA, FRCP Nephrology Section, General Internal Medicine University of Texas MD Anderson Cancer Center Houston Texas USA
ISBN 978-1-4939-2659-6 (eBook)
Library of Congress Control Number: 2015938451 Springer New York Heidelberg Dordrecht London © Springer Science+Business Media New York 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer Science+Business Media LLC New York is part of Springer Science+Business Media (www.springer.com)
Foreword
We all recognize that major advances have been made in the treatment of patients with leukemia, lymphoma, breast cancer, prostate cancer, colon cancer, and several other malignancies over the past few decades. As a consequence, the number of survivors after a cancer diagnosis has increased from 3 million in 1971 to about 14.5 million today, which experts attribute to advancements in diagnosis, treatment, and supportive care. The field of hematology–oncology has exponentially grown to include rationally designed biologics and small molecules that target dysregulated pathways. Though the use of these new agents has led to remarkable improvement in overall survival, some of these drugs cause nephrotoxicity. More importantly, since cancer is primarily a disease affecting older people, the renal function of patients at the time of diagnosis may be compromised due to expected decline in renal function attributed to aging cells. Given that up to a quarter of patients with a cancer diagnosis will develop new onset renal impairment, a new discipline that aims to understand and manage the chal
Data Loading...
